
Global Retinal Biologics Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Retinal Biologics market size will reach US$ million by 2031.
Many retinal biologics have been approved by the Food and Drug Administration (FDA), the European Medicine Agency (EMA) and the China Food and Drug Administration (CFDA) for the treatment of retinal diseases. Advancements in technologies and new mechanism of action for different biologics to treat retinal diseases are anticipated to boost the retinal biologics market.
United States market for Retinal Biologics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Retinal Biologics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Retinal Biologics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Retinal Biologics players cover Spark Therapeutics, Inc, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc, AbbVie Inc, Johnson & Johnson Services, Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Retinal Biologics Industry Forecast” looks at past sales and reviews total world Retinal Biologics sales in 2024, providing a comprehensive analysis by region and market sector of projected Retinal Biologics sales for 2025 through 2031. With Retinal Biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Retinal Biologics industry.
This Insight Report provides a comprehensive analysis of the global Retinal Biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Retinal Biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Retinal Biologics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Retinal Biologics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Retinal Biologics.
This report presents a comprehensive overview, market shares, and growth opportunities of Retinal Biologics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Macular Degeneration
Diabetic Retinopathy
Diabetic Macular Edema
Uveitis
Others
Segmentation by Application:
Hospitals
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Spark Therapeutics, Inc
F. Hoffmann-La Roche Ltd
Regeneron Pharmaceuticals, Inc
AbbVie Inc
Johnson & Johnson Services, Inc
Amgen Inc
Please note: The report will take approximately 2 business days to prepare and deliver.
Many retinal biologics have been approved by the Food and Drug Administration (FDA), the European Medicine Agency (EMA) and the China Food and Drug Administration (CFDA) for the treatment of retinal diseases. Advancements in technologies and new mechanism of action for different biologics to treat retinal diseases are anticipated to boost the retinal biologics market.
United States market for Retinal Biologics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Retinal Biologics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Retinal Biologics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Retinal Biologics players cover Spark Therapeutics, Inc, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc, AbbVie Inc, Johnson & Johnson Services, Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Retinal Biologics Industry Forecast” looks at past sales and reviews total world Retinal Biologics sales in 2024, providing a comprehensive analysis by region and market sector of projected Retinal Biologics sales for 2025 through 2031. With Retinal Biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Retinal Biologics industry.
This Insight Report provides a comprehensive analysis of the global Retinal Biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Retinal Biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Retinal Biologics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Retinal Biologics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Retinal Biologics.
This report presents a comprehensive overview, market shares, and growth opportunities of Retinal Biologics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Macular Degeneration
Diabetic Retinopathy
Diabetic Macular Edema
Uveitis
Others
Segmentation by Application:
Hospitals
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Spark Therapeutics, Inc
F. Hoffmann-La Roche Ltd
Regeneron Pharmaceuticals, Inc
AbbVie Inc
Johnson & Johnson Services, Inc
Amgen Inc
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
83 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Retinal Biologics Market Size by Player
- 4 Retinal Biologics by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Retinal Biologics Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.